CP
PFE icon

Corbenic Partners’s Pfizer PFE Stock Holding History

Corbenic Partners’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$8.69M Buy
165,745
+969
+0.6% +$49.4K 2.29% 12
2022
Q1 		$8.53M Buy
164,776
+5,657
+4% +$294K 1.85% 15
2021
Q4 		$9.4M Buy
159,119
+8,131
+5% +$403K 1.82% 11
2021
Q3 		$6.49M Sell
150,988
-6,511
-4% -$288K 1.58% 19
2021
Q2 		$6.17M Buy
157,499
+6,380
+4% +$248K 1.62% 14
2021
Q1 		$5.47M Buy
151,119
+26,259
+21% +$932K 1.4% 21
2020
Q4 		$4.6M Sell
124,860
-5,174
-4% -$190K 1.9% 19
2020
Q3 		$4.53M Sell
130,034
-31
-0% -$1.09K 2.17% 12
2020
Q2 		$4.04M Sell
130,065
-285
-0.2% -$9.68K 2.21% 14
2020
Q1 		$4.04M Buy
130,350
+18,688
+17% +$637K 3.12% 10
2019
Q4 		$4.15M Buy
+111,662
New +$3.98M 3.01% 11
2017
Q4 		$2.52M Sell
73,490
-510
-0.7% -$17.4K 3.17% 14
2017
Q3 		$2.51M Sell
74,000
-2,090
-3% -$67.2K 3.3% 11
2017
Q2 		$2.42M Sell
76,090
-8,085
-10% -$255K 3.37% 10
2017
Q1 		$2.73M Sell
84,175
-11,591
-12% -$365K 3.35% 12
2016
Q4 		$2.95M Sell
95,766
-1,430
-1% -$43.7K 3.16% 13
2016
Q3 		$3.12M Sell
97,196
-4,768
-5% -$159K 3.32% 11
2016
Q2 		$3.41M Sell
101,964
-7,906
-7% -$252K 3.49% 11
2016
Q1 		$3.09M Buy
109,870
+1,349
+1% +$38.5K 3.15% 14
2015
Q4 		$3.32M Sell
108,521
-38,683
-26% -$1.22M 3.19% 12
2015
Q3 		$4.39M Sell
147,204
-21,828
-13% -$700K 3.97% 9
2015
Q2 		$5.38M Sell
169,032
-11,504
-6% -$375K 4.59% 4
2015
Q1 		$5.96M Buy
180,536
+12,006
+7% +$382K 4.81% 5
2014
Q4 		$4.98M Buy
168,530
+25,200
+18% +$723K 3.66% 7
2014
Q3 		$4.02M Sell
143,330
-662
-0.5% -$18.6K 3.15% 10
2014
Q2 		$4.05M Buy
143,992
+50,718
+54% +$1.45M 3.11% 12
2014
Q1 		$2.84M Sell
93,274
-224
-0.2% -$6.68K 2.26% 16
2013
Q4 		$2.72M Buy
93,498
+13,665
+17% +$398K 2.58% 14
2013
Q3 		$2.18M Buy
79,833
+8,450
+12% +$230K 2.9% 14
2013
Q2 		$1.9M Buy
+71,383
New +$1.97M 1.77% 23

Other funds holding PFE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Corbenic Partners's PFE Position: Q2 2022 in Review

Corbenic Partners increased its Pfizer (PFE) stake by 0.59% in Q2 2022, buying an estimated $49.4K and bringing the position to 165,745 shares worth $8.69M. The position accounts for 2.29% of the portfolio, ranked #12.

Corbenic Partners first reported a position in PFE in Q2 2013 and has held it in 30 quarters since. The position peaked at $9.4M in Q4 2021. 3,157 funds tracked by Wall St. Rank hold PFE as of Q2 2022.

  • Corbenic Partners held 165,745 shares of Pfizer worth $8.69M as of Q2 2022.
  • Corbenic Partners bought 969 Pfizer shares in Q2 2022, an estimated $49.4K.
  • Pfizer made up 2.29% of Corbenic Partners's portfolio in Q2 2022, its #12 holding.
  • Corbenic Partners first reported a position in Pfizer in Q2 2013 and has held it in 30 quarters since.
  • Corbenic Partners's Pfizer position peaked at $9.4M in Q4 2021.
  • 3,157 funds tracked by Wall St. Rank held Pfizer as of Q2 2022.

Based on Corbenic Partners's 13F filing for Q2 2022, filed 25 Jul 2022.